中南大学近日发布情况通报,确认其附属湘雅二医院及湘雅医院的三篇医学论文存在伪造篡改数据、不当署名等学术不端行为 1。针对相关责任人员,学校依据相关规定作出了降低岗位等级、取消晋升资格及限制承担财政性科技项目等处罚 1。校方强调对学术不端行为持“零容忍”态度,并将加强科研作风建设与监督体系 1。
经查实,2025年发表于《Journal of Translational Medicine》的论文《Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma》,第一作者为邓某某,通讯作者为赵某,查实存在伪造篡改实验研究数据和图表、不当署名以及违反科研伦理规范等问题 1。另一篇2026年发表于《Cell Death & Disease》的论文《Tumor-infiltrating B cells inhibit nasopharyngeal carcinoma metastasis》,第一作者为蔡某,共同第一作者为谭某某,通讯作者为赵某,查实存在伪造篡改实验研究数据和图表及不当署名行为 1。此外,2026年发表于《Scientific Reports》的论文《Arvanil reverses cisplatin resistance in ovarian cancer by activating HMOX1-driven ferroptosis》,通讯作者为邓某某,查实存在伪造篡改实验研究数据和图表的行为 1。
在处罚措施方面,中南大学决定对邓某某、赵某降低专业技术岗位等级,并在5年内取消职务职称晋升等资格,同时规定两人在10年内不得承担财政性资金支持科技活动 1。对于蔡某、谭某某,学校给予5年内取消职务职称晋升等资格,以及5年内不得承担财政性资金支持科技活动的处罚 1。其他涉及的相关作者予以学术诫勉谈话 1。
Central South University has issued a formal notification confirming that three medical papers published by researchers from its affiliated Xiangya Second Hospital and Xiangya Hospital involved academic misconduct. The confirmed violations include the fabrication and tampering of experimental data and charts, improper authorship attribution, and breaches of research ethics standards. 1 The university stated that it maintains a "zero tolerance" policy toward such behavior and is strengthening its supervision systems to improve the style of scientific research conduct. 1
The investigation identified specific irregularities in three distinct publications. A paper titled "Ferroptosis inhibition via the ROS-GPX4 axis drives microplastic-induced malignant progression of nasopharyngeal carcinoma," published in the Journal of Translational Medicine in 2025, was found to contain fabricated and tampered experimental data, along with improper signatures and ethical breaches. The first author was Deng XX, and the corresponding author was Zhao X. 1 Similarly, a study on tumor-infiltrating B cells inhibiting nasopharyngeal carcinoma metastasis, published in Cell Death & Disease in 2026, was cited for falsified data and improper authorship practices. The first author was Cai X, the co-first author was Tan XX, and the corresponding author was Zhao X. 1 The third flagged article, which appeared in Scientific Reports in 2026 and discussed how Arvanil reverses cisplatin resistance in ovarian cancer, was confirmed to involve fabricated and altered experimental data and charts. The corresponding author was Deng XX. 1
In response to these findings, the university has imposed strict penalties on the responsible individuals. Deng XX and Zhao X have had their professional technical ranks lowered and are barred from promotion or title advancement for five years; additionally, they are prohibited from undertaking science and technology activities funded by fiscal support for ten years. 1 Cai X and Tan XX face a five-year ban on promotions and title advancements, as well as a five-year prohibition from undertaking fiscal-funded scientific activities. 1 Other authors associated with these works have received admonitory talks regarding academic integrity. 1
评论
还没有评论,欢迎留下第一条。